BioNTech SE reiterated revenue guidance for the full year 2024. For the period, Company expects revenues to be in the range of ?2.5 billion to ?3.1 billion.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
92.89 USD | -1.29% | -9.20% | -11.99% |
02:57pm | BioNTech, CEPI Expand Partnership for mRNA Vaccine Ecosystem in Africa | MT |
02:38pm | BioNTech gets $145 mln funding for African vaccine plants | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.99% | 22.71B | |
+8.67% | 115B | |
+9.66% | 105B | |
+2.21% | 21.83B | |
-10.88% | 18.18B | |
-41.90% | 16.52B | |
-16.74% | 16.01B | |
+1.66% | 14.14B | |
+20.73% | 10.71B | |
-30.21% | 7.6B |
- Stock Market
- Equities
- BNTX Stock
- News BioNTech SE
- BioNTech SE Reiterates Revenue Guidance for the Full Year 2024